Hanlan Liu
About Hanlan Liu
Hanlan Liu: SVP, Early Pipeline and Non Clinical Development
Hanlan Liu holds the position of Senior Vice President of Early Pipeline and Non Clinical Development. In this role, he oversees early-stage drug development processes and preclinical studies. He plays a pivotal role in steering projects from conceptual stages through initial development, ensuring that early scientific advancements align with broader business strategies.
Hanlan Liu's Education and Expertise
Hanlan Liu has an extensive academic background, holding both a Ph.D. and an MBA. This combination of scientific expertise and business acumen enables him to bridge the gap between research and commercialization. His advanced education equips him with the skills necessary to manage complex development pipelines and contribute meaningfully to strategic decision-making in the field of non-clinical development.
Hanlan Liu's Presentations at Industry Conferences
Hanlan Liu has shared his expertise at significant industry conferences. In January 2024, he presented at the Keystone Symposia on Emerging Cellular Therapies, highlighting advancements and trends in the field. Earlier, in December 2023, he presented at the American Society of Hematology (ASH), discussing critical insights and developments pertinent to hematology.
Hanlan Liu's Research Publications in Renowned Journals
Hanlan Liu has contributed to multiple high-impact research journals. His work has been published in Nature Communications, Molecular Therapy, Trends in Cancer, and Frontiers in Immunology. Furthermore, he has authored pieces for Nature Reviews Immunology. These publications underscore his contributions to the scientific community and highlight his expertise in fields such as immunology, cancer research, and cellular therapies.